CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 27 enrolled
Drug / intervention
suvorexant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02849548
NCT02849548Phase 4Completed
CompareCT.gov

Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?

Howard University·interventional·Posted Jul 29, 2016·Updated Jun 2, 2023

In Brief

A Phase 4 clinical trial evaluating suvorexant and placebo for Posttraumatic Stress Disorder. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The purpose of this study is to examine effects of blocking the orexin system with suvorexant after exposure-based intervention for posttraumatic stress disorder (PTSD) on sleep, PTSD symptoms, and intersession habituation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosttraumatic Stress Disorder
CountriesUnited States
CollaboratorsGeorgetown-Howard Universities Center for Clinical and Translational Science, National Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 29, 2016
Enrollment StartJan 3, 2017
Primary CompletionMay 17, 2021
Study CompletionMay 19, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.9 years ago

Interventions

suvorexantdrug

First in class orexin antagonist approved by the FDA for the treatment of insomnia

placeboother

Pill with inactive ingredients